Lytix Biopharma AS has successfully raised 50 million NOK. 71 429 new shares have been issued for a subscription price of NOK 700 per share from existing and new shareholders.

CEO Unni Hjelmaas is pleased that Lytix Biopharma now has secured funding for the company's cancer and infection projects in 2015.

- We are very satisfied with the interest the company has been shown in today’s challenging capital market, says the chairman Knut Eidissen.

In the issue the following insiders have been allocated shares:
Norinnova Invest AS, vice chairman of the board Karl-Johan Jakola, 1 428 shares.
North Murray AS, controlled by board member Gert Wilhelm Munthe, 14 000 shares.

Arctic Securities has been the advisor and facilitator of this capital raise.

Further information:

Company contact: Unni Hjelmaas CEO
Tel (+47) 915 19 651, e-mail: unni.hjelmaas@lytixbiopharma.com